|Medtronic to Unveil Pivotal Trial Results for Hybrid Closed Loop System at American Diabetes Association 2016 Meeting|
DUBLIN - June 7, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced its schedule of notable sessions that will be presented at the 76th Scientific Sessions of the American Diabetes Association in New Orleans. Among the presentations are late breaking pivotal trial results of the Hybrid Closed Loop system, pivotal trial results for the company's fourth generation sensor and further study of the company's SmartGuard(TM) technology. Hybrid Closed Loop system is approved for investigational use only in the U.S., and many devices being presented at ADA are also investigational use only.
"At ADA 2016, we have a number of important data presentations about our marketed products and key products in our pipeline, most notably our Hybrid Closed Loop system and next generation sensor," said Francine R. Kaufman, M.D., chief medical officer and vice president of global, clinical and medical affairs for Medtronic Diabetes. "We are proud to be the first company to present results of a pivotal trial of a closed loop system, which is designed to automatically control glucose levels 24 hours a day with less input from patients, as we continue toward our goal of helping people with diabetes enjoy greater freedom and better health."
"The ability for people with diabetes to achieve better glucose control and live longer, healthier lives has significantly improved with insulin pumps and continuous glucose monitoring systems. However, patients must still make frequent decisions each day while using today's systems," said Richard M. Bergenstal, M.D., of the International Diabetes Center in Minneapolis. "Simplifying this self-management and adding a little peace of mind with this more automated Hybrid Closed Loop system would impact these patients' lives in a very meaningful way."
Type 2 Diabetes
Analyst and Investor Briefing
About the Diabetes Group at Medtronic (www.medtronicdiabetes.com)
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.